record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
contested
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; placebo-controlled clinical trial where source reports control arm · Homo sapiens
proof impact
packet context3 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; placebo-controlled clinical trial where source reports control arm
evidence type
experimental
species
Homo sapiens
evidence spans
Aducanumab's EMERGE and ENGAGE phase 3 trials produced discordant efficacy results, making aducanumab a contested anti-amyloid translation precedent.
EMERGE and ENGAGE phase 3 trial records and FDA review materials · curator_source · https://clinicaltrials.gov/search?term=aducanumab%20EMERGE%20ENGAGE
conditions
Provenance
source title
EMERGE and ENGAGE phase 3 trial records and FDA review materials
authors
reviewer:will-blair-bot
Aducanumab's EMERGE and ENGAGE phase 3 trials produced discordant efficacy results, making aducanumab a contested anti-amyloid translation precedent.
vs_4d9acc27f5c5fd4f · source:EMERGE and ENGAGE phase 3 trial records and FDA review materials|section:curator_source · manual_curation
outgoing
vf_9ded3333a52f3e58aducanumab remains a cautionary same-target precedent for interpreting antibody benefit
incoming
extends · vf_4d8aa40cc734ab93
extends · vf_56f893a9fe9651de
events
vev_a20df21281cce197finding.reviewedParallel phase 3 trials were discordant; preserve plural interpretation.
reviewer:will-blair-bot · 2026-05-06
vev_d5d58497546a1909finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_f99ca39b6d2e4067finding.confidence_revisedDiscordant phase 3 record lowers confidence in aducanumab as a stable translation anchor.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_51af45c632c05070finding.reviewParallel phase 3 trials were discordant; preserve plural interpretation.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_953ca8193cb056d3finding.confidence_reviseDiscordant phase 3 record lowers confidence in aducanumab as a stable translation anchor.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_ccc97ca5ce161801finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.